Sanofi Consumer Healthcare India Limited (SANOFICONR) investor relations material

Business performance and transformation

• Achieved revenue from operations of ₹8,784 million in FY2025, with leading brands like Avil, Allegra, Combiflam, and DePura holding top market positions.

• Operating profit and profit after tax grew by 13% and 33% respectively, with revenue up 21% versus FY2024.

• Underwent significant organizational changes, including demerger, new identity, and successful listing.

• Built a high-performing team, recognized as a preferred workplace, and focused on wellness and performance-driven culture.

• CD&R acquired a controlling stake in the global business, enabling further transformation.

Strategic focus and market opportunities

• Shifted from a pharma-driven to a consumer healthcare approach, emphasizing brand equity and self-care.

• Identified high growth potential in allergy, pain, and vitamin D categories, with significant headroom for penetration.

• Leveraged strong brand equity and consumer engagement, with millions of followers and high brand recall.

• Consumers increasingly self-medicate and seek health information online, with influencers playing a key role.

• Competitive investment in media, HCP, and store coverage is imperative to drive growth.

Demand generation and execution

• Unlocked demand levers across healthcare professionals, consumers, and point of sale after a period of constrained demand.

• Strategy centers on synergistic demand generation through HCP and self-choice, scaling both HCP initiation and consumer engagement.

• Doubled doctor reach face-to-face and expanded digital engagement to over 50,000 doctors.

• Digital-first campaigns and targeted social media spends have expanded multimedia reach to 60 million.

• Increased direct retail coverage and chemist recommendations, doubling store coverage.